{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-21-059489","form_type":"8-K","ticker":"NKTR","cik":"0000906709","company_name":"NEKTAR THERAPEUTICS","filed_at":"2021-11-15T23:59:59+00:00","discovered_at":"2026-05-14T18:04:16.161238+00:00","generated_at":"2026-06-28T08:51:15.913387+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"confidence":"high","headline":"Nektar Therapeutics appoints Diana M. Brainard, M.D. to board of directors","bullets":["Dr. Brainard appointed as Class III Director effective Nov 11, 2021; term expires at 2022 annual meeting.","Board determined she is independent under SEC and Nasdaq rules.","She receives standard non-employee director compensation: initial option for 36,720 shares vesting over 3 years, RSU for 18,360 shares vesting over 3 years, and $65,000 annual cash retainer."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-21-059489","json":"https://secwatch.observer/filing/0001213900-21-059489.json","markdown":"https://secwatch.observer/filing/0001213900-21-059489.md","text":"https://secwatch.observer/filing/0001213900-21-059489.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/906709/000121390021059489/0001213900-21-059489-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/906709/000121390021059489/ea150696-8k_nektartherap.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-28T08:51:15.913387+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"0c1c3ae0dd","claim":"Diana M. Brainard, M.D. was appointed as Class III Director at NEKTAR THERAPEUTICS.","evidence_excerpt":"On November 11, 2021, Diana M. Brainard, M.D. was appointed to the board of directors (the “ Board ”) of Nektar Therapeutics, a Delaware corporation (the “ Company ”), as a Class III Director","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/906709/000121390021059489/0001213900-21-059489-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Class III Director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}